A61K 40/4562
Salmonella
Official title: {Salmonella; Shigella}
A61K40/4562 (Salmonella) appears on 5 US grants and 16 published applications in this corpus.
Search patents in A61K- Granted patents
- 5
- Published applications
- 16
- Assignees
- 11
- Inventors
- 30
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 0 |
| 2025 | 3 | 1 |
By publication year.
Recent patents
- Engineered immunostimulatory bacterial strains and uses thereof15 Jul 2025US 12,357,661 B2Actym Therapeutics, Inc.
- Engineered immunostimulatory bacterial strains and uses thereof18 Feb 2025US 12,226,439 B2Actym Therapeutics, Inc.
- Engineered immunostimulatory bacterial strains and uses thereof21 Jan 2025US 12,201,653 B2Actym Therapeutics, Inc.
- Engineered immunostimulatory bacterial strains and uses thereof10 Oct 2023US 11,779,612 B2Actym Therapeutics, Inc.
- Recombinant bacterium and uses thereof10 Jan 2017US 9,539,313 B2National Research Council of Canada
- Engineered immunostimulatory bacterial strains and uses thereof13 Nov 2025US 2025/0345369 A1Actym Therapeutics, Inc.
- Tumor-associated peptides and uses thereof30 Nov 2023US 2023/0381291 A1Humanitas Mirasole S.P.A.
- Engineered immunostimulatory bacterial strains and uses thereof9 Mar 2023US 2023/0072505 A1Actym Therapeutics, Inc.
- Engineered immunostimulatory bacterial strains and uses thereof8 Sep 2022US 2022/0280577 A1Actym Therapeutics, Inc.
- Engineered immunostimulatory bacterial strains and uses thereof4 Feb 2021US 2021/0030813 A1Actym Therapeutics, Inc.
Most cited
By later US patents